ConductScience.org, home

Paper3979912

Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.

Campieri M and 8 others. Gut, 1985. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Papers, record 3979912. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3979912

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.
PubMed
Journal
Gut
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
3.48
iCite
Revised in PubMed
2019-05-01
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Campieri MM
2Lanfranchi GAG A
3Boschi SS
4Brignola CC
5Bazzocchi GG
6Gionchetti PP
7Minguzzi MRM R
8Belluzzi AA
9Labò GG

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aminosalicylic AcidsMajor topic
Colitis, UlcerativeMajor topic
RectumMajor topic
Administration, Topical
Enema
Humans
Intestinal Absorption
Mesalamine

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16121181Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression.Lancet1982https://conductscience.org/library/papers/6121181PubMed
220791817Nephrotoxic lesions from 5-aminosalicylic Acid.Br Med J1972https://conductscience.org/library/papers/20791817PubMed
36114321Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.Lancet1981https://conductscience.org/library/papers/6114321PubMed
46126289Rectal drug administration: clinical pharmacokinetic considerations.Clin Pharmacokinet1982https://conductscience.org/library/papers/6126289PubMed
51247769Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.Br Med J1976https://conductscience.org/library/papers/1247769PubMed
66107853Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.N Engl J Med1980https://conductscience.org/library/papers/6107853PubMed
76118605Disodium azodisalicylate in ulcerative colitis.Lancet1981https://conductscience.org/library/papers/6118605PubMed
86110627
On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon.
Hepatogastroenterology1980https://conductscience.org/library/papers/6110627PubMed
94146729Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.N Engl J Med1973https://conductscience.org/library/papers/4146729PubMed
106107263Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut1980https://conductscience.org/library/papers/6107263PubMed
114405598Distribution studies of salicylazosulfapyridine and its metabolites.Gastroenterology1973https://conductscience.org/library/papers/4405598PubMed
127173720Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut1982https://conductscience.org/library/papers/7173720PubMed
1371177895-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.Gastroenterology1982https://conductscience.org/library/papers/7117789PubMed
146117565Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine.J Chromatogr1981https://conductscience.org/library/papers/6117565PubMed
156113021Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.Br Med J (Clin Res Ed)1981https://conductscience.org/library/papers/6113021PubMed
164800686Absorption of salicylic acid from the perfused human rectum.Acta Pharmacol Toxicol (Copenh)1973https://conductscience.org/library/papers/4800686PubMed
174402886Absorption, metabolism, and excretion of salicylazosulfapyridine in man.Clin Pharmacol Ther1972https://conductscience.org/library/papers/4402886PubMed
19223947Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema.Gut1979https://conductscience.org/library/papers/223947PubMed
206381184A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.Digestion1984https://conductscience.org/library/papers/6381184PubMed
216669934Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose.Scand J Gastroenterol1983https://conductscience.org/library/papers/6669934PubMed

See all 22 referencesDownload CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
33138176Anti-Inflammatory Activity of Chitosan and 5-Amino Salicylic Acid Combinations in Experimental Colitis.Pharmaceutics2020https://conductscience.org/library/papers/33138176PubMed
29752633Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.Clin Pharmacokinet2019https://conductscience.org/library/papers/29752633PubMed
24707159Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.World J Gastroenterol2014https://conductscience.org/library/papers/24707159PubMed
16225364How important is onset of action in ulcerative colitis therapy?Drugs2005https://conductscience.org/library/papers/16225364PubMed
12534636Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability.Br J Clin Pharmacol2003https://conductscience.org/library/papers/12534636PubMed
10976656Clinical pharmacokinetics of slow release mesalazine.Clin Pharmacokinet2000https://conductscience.org/library/papers/10976656PubMed
10759687Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.Br J Clin Pharmacol2000https://conductscience.org/library/papers/10759687PubMed
9691909What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?Gut1998https://conductscience.org/library/papers/9691909PubMed
9149065Hypersensitivity to 5-ASA suppositories.Dig Dis Sci1997https://conductscience.org/library/papers/9149065PubMed
8801202A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.Gut1996https://conductscience.org/library/papers/8801202PubMed
8404405Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.Dig Dis Sci1993https://conductscience.org/library/papers/8404405PubMed
7959212Mesalazine induced interstitial nephritis.Gut1994https://conductscience.org/library/papers/7959212PubMed
3678967Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.Gut1987https://conductscience.org/library/papers/3678967PubMed
3319460Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.Dig Dis Sci1987https://conductscience.org/library/papers/3319460PubMed
3207553Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3207553PubMed
2899536Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.Gut1988https://conductscience.org/library/papers/2899536PubMed
27028895-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.Dig Dis Sci1989https://conductscience.org/library/papers/2702889PubMed
2684592Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2684592PubMed
2651087Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2651087PubMed
1884566Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.Clin Pharmacokinet1991https://conductscience.org/library/papers/1884566PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3979912

GET https://conductscience.org/api/papers/v1/3979912/references?page=2